Guidelines recommend pharmacists provide take-home naloxone to all opioid usersTake-home naloxone kits are publicly funded in all Canadian provinces and territories and have been shown to effectively reduce opioid-related deaths. Emgality (galcanezumab) now indicated to reduce cluster headache frequencyCGRP binding antibody is first drug approved by Health Canada to help prevent episodic cluster headaches New Canadian consensus guidelines for pharmacist prescribing of naloxone All patients receiving an opioid should be provided with take-home naloxone and counselled by a pharmacist Be alert for potential drug interactions with medical and recreational cannabis Review provides a comprehensive list of drug-drug interactions, with particular focus on Rx drugs with a narrow therapeutic index Acetaminophen–ibuprofen fixed-dose combo product coming soon to Canada Indicated in adults for short-term management of mild to moderate acute pain and for reduction of fever Medical cannabis and the unmet needs of chronic pain in Canada Health Canada examines link between ibuprofen and 'flesh-eating disease' in children with chickenpox Finds no association between use of nonprescription ibuprofen-containing products and the occurrence of necrotizing fasciitis What is the best treatment for medication overuse headache? Study examines three treatment strategies for medication overuse headache New guidelines seek greater safety in post-op prescribing of opioids Managing sleep disturbances in chronic pain The first approach to managing sleep disturbances from chronic pain is to educate the patient on the importance of sleep hygiene principles First Previous 15 16 17 18 19 Next Last
